Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Table 2. Summary of reports on G-CSF producing UCC. Age Stage Histology G-CSF (pg/ml) WBC (x103/ul) CRP (mg/dl) Initial Tx PFS (M) Rec site Rec Tx OS (M) Reference 56 IB2 Sq 197 12.9 7.0 Surgery 0.5 Parametrium BSC 2 6 39 IB2 Sq 50 13.9 1.8 Surgery-RT 0.25 Brain, skin, lung CT 5 7 72 IB2 Sq 248 20.6 4.8 CCRT 6 Uterus. lung S-CT 15 7 64 IIA2 Cs 1500 48.0 NA RT 0.25 Skin, bone RT 2 8 64 IIB Ad 148 11.8 3.8 RT 0.25 SCLN, liver,lung BSC 3 9 43 IIB Sq 323 28.3 6.2 CCRT 2 SCLN, liver,lung BSC 5 Present case 58 IIB Sq 58 22.5 6.6 CCRT NA NA NA 24 10 75 IIB NA 223 31.7 2.6 CIRT - - - 108+ 11 41 IIIB Sq 106 34.4 1.5 CCRT 3 Liver CT 9 7 76 IIIB Sq 642 31.1 5.4 CIRT - - - 30+ 11 71 IIIB Sq 195 30.0 NA RT - - - 8+ 12 59 IVB Sq 875 13.7 0.6 RT-AC 1 Lung, LN BSC 3 7 70 IVB Sm 269 17.1 0.8 CT-RT-CT 0 Liver BSC 11 13 G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown. G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white blood cell count before initial treatment; CRP, serum C-reactive protein before initial treatment; Tx, treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT, chemotherapy; PFS, progression free survival; M, months; Rec, recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive care; OS, overall survival; +, still alive. Laboratory test results before initial treatment are shown.